Show simple item record

dc.contributor.authorPlaza Díaz, Julio 
dc.contributor.authorÁlvarez Mercado, Ana Isabel 
dc.date.accessioned2020-12-18T12:02:58Z
dc.date.available2020-12-18T12:02:58Z
dc.date.issued2020-11-07
dc.identifier.citationPlaza-Díaz, J., Solís-Urra, P., Rodríguez-Rodríguez, F., Olivares-Arancibia, J., Navarro-Oliveros, M., Abadía-Molina, F., & Álvarez-Mercado, A. I. (2020). The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage. International Journal of Molecular Sciences, 21(21), 8351. [doi:10.3390/ijms21218351]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/65034
dc.description.abstractLiver disease encompasses pathologies as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, alcohol liver disease, hepatocellular carcinoma, viral hepatitis, and autoimmune hepatitis. Nowadays, underlying mechanisms associating gut permeability and liver disease development are not well understood, although evidence points to the involvement of intestinal microbiota and their metabolites. Animal studies have shown alterations in Toll-like receptor signaling related to the leaky gut syndrome by the action of bacterial lipopolysaccharide. In humans, modifications of the intestinal microbiota in intestinal permeability have also been related to liver disease. Some of these changes were observed in bacterial species belonging Roseburia, Streptococcus, and Rothia. Currently, numerous strategies to treat liver disease are being assessed. This review summarizes and discusses studies addressed to determine mechanisms associated with the microbiota able to alter the intestinal barrier complementing the progress and advancement of liver disease, as well as the main strategies under development to manage these pathologies. We highlight those approaches that have shown improvement in intestinal microbiota and barrier function, namely lifestyle changes (diet and physical activity) and probiotics intervention. Nevertheless, knowledge about how such modifications are beneficial is still limited and specific mechanisms involved are not clear. Thus, further in-vitro, animal, and human studies are needed.es_ES
dc.description.sponsorshipNational Agency for Research and Development (ANID) BECAS Chile 72180543es_ES
dc.language.isoenges_ES
dc.publisherMdpies_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectLiver diseaseses_ES
dc.subjectIntestinal barrieres_ES
dc.subjectIntestinal permeabilityes_ES
dc.subjectMicrobiotaes_ES
dc.titleThe Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Managees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/ijms21218351
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España